Detailed Narrative
Commercial Business Strength and Avadel Acquisition
Alkermes reported strong FY25 financial results, with proprietary product net sales growing 9% year-over-year to approximately $1.2 billion. The recent acquisition of Avadel, which closed in February 2026, significantly strengthens the commercial platform by adding LUMRYZ and accelerating Alkermes' entry into the sleep medicine market. This strategic move is expected to contribute meaningfully to future revenue and growth, with LUMRYZ projected to generate $350 million to $370 million in total revenue for FY26.
Alixorexton Development and Breakthrough Therapy Designation
Alixorexton, Alkermes' most advanced orexin candidate, is poised to enter Phase III in narcolepsy in Q1 2026, following a rigorous Phase II program and the recent grant of FDA Breakthrough Therapy Designation. The end-of-Phase II meeting with the FDA confirmed the registration plan, which includes three 12-week randomized, placebo-controlled studies across narcolepsy type 1 and type 2. The program will feature both once-daily and split-dosing regimens, aiming to differentiate the product and address unmet needs in central disorders of hypersomnolence.
Orexin Pipeline Expansion
Beyond alixorexton, Alkermes is advancing other orexin 2 receptor agonist candidates, ALKS 7290 and ALKS 4510, both currently in Phase I studies. ALKS 7290 is being developed for ADHD, with plans to initiate a multi-dose Phase Ib study in adult patients and a Phase II study in H2 2026, targeting a significant unmet need. ALKS 4510 is being developed for fatigue associated with neurodegenerative disorders like MS and Parkinson's, with a Phase IIa study expected to initiate in 2026. These programs represent a new vertical of growth and expansion in neuroscience.
LUMRYZ Performance and IH Opportunity
LUMRYZ, acquired through Avadel, generated approximately $279 million in net sales in FY25 and treated about 3,500 patients by year-end, a 40% increase from Q4 2024. The product, a once-at-bedtime sodium oxybate for narcolepsy, addresses a significant unmet need, with an estimated 50,000 oxybate-eligible patients. Alkermes also expects data from the REVITALIZE Phase III study of LUMRYZ in idiopathic hypersomnia (IH) in Q2 2026, which, if positive, could lead to an sNDA submission and potential launch in early 2028, expanding its market reach.
Leadership Transition
Richard Pops announced his transition from CEO to Chairman, with current Chief Operating Officer Blair Jackson assuming the CEO role this summer. This leadership change comes at a time of significant strength and growth for the company, following the successful transformation into a proprietary products company and the advancement of a promising pipeline. The transition is described as a logical step, with confidence in continued momentum and value creation under new leadership.
Oxybate vs. Orexin Agonists Co-Treatment
Management clarified that orexin agonists primarily address wakefulness, while oxybates target fragmented nighttime sleep. While orexin agonists may suffice for many patients, a cohort could benefit from both, especially those needing consolidated nighttime sleep. Alkermes, now with assets in both categories (LUMRYZ and alixorexton), plans to generate data for payers to support the value of co-treatment for specific patient populations, viewing this as an evidence-building pathway rather than a registrational one.
ADHD and Neurodegenerative Fatigue Market Opportunities
The company sees significant potential in ALKS 7290 for ADHD, noting its preclinical profile showing efficacy across concentration and impulsivity domains, potentially offering a new therapeutic option beyond stimulants and non-stimulants. For ALKS 4510, targeting fatigue in MS and Parkinson's, the large patient populations (1 million each in the U.S.) represent a substantial opportunity, with the current Phase I studies paving the way for Phase IIa initiation this year.